ACTN3 genotype infuences muscle performance through the regulation of calcineurin signaling

Jane T. Seto, Kate G R Quinlan, Monkol Lek, Xi Fiona Zheng, Fleur Garton, Daniel G MacArthur, Marshall W. Hogarth, Peter J. Houweling, Paul Gregorevic, Nigel Turner, Gregory J Cooney, Nan Yang, Kathryn N North

Research output: Contribution to journalArticleResearchpeer-review

78 Citations (Scopus)


α-Actinin-3 deficiency occurs in approximately 16% of the global population due to homozygosity for a common nonsense polymorphism in the ACTN3 gene. Loss of α-actinin-3 is associated with reduced power and enhanced endurance capacity in elite athletes and nonathletes due to "slowing" of the metabolic and physiological properties of fast fibers. Here, we have shown that α-actinin-3 deficiency results in increased calcineurin activity in mouse and human skeletal muscle and enhanced adaptive response to endurance training. α-Actinin-2, which is differentially expressed in α-actinin-3-deficient muscle, has higher binding affinity for calsarcin-2, a key inhibitor of calcineurin activation. We have further demonstrated that α-actinin-2 competes with calcineurin for binding to calsarcin-2, resulting in enhanced calcineurin signaling and reprogramming of the metabolic phenotype of fast muscle fibers. Our data provide a mechanistic explanation for the effects of the ACTN3 genotype on skeletal muscle performance in elite athletes and on adaptation to changing physical demands in the general population. In addition, we have demonstrated that the sarcomeric α-actinins play a role in the regulation of calcineurin signaling.

Original languageEnglish
Pages (from-to)4255-4263
Number of pages9
JournalJournal of Clinical Investigation
Issue number10
Publication statusPublished - 1 Oct 2013
Externally publishedYes

Cite this